All articles tagged with #olaparib
Dartmouth researchers find that the common blood pressure drug telmisartan can markedly enhance the cancer drug olaparib, boosting DNA damage and immune signaling to potentially extend PARP inhibitor benefits to more patients, with two clinical trials already launched in prostate and ovarian cancer.
A new pre-surgery treatment combining chemotherapy and the targeted drug olaparib, with a carefully timed 48-hour gap, has achieved a 100% survival rate in a clinical trial for aggressive inherited breast cancers linked to BRCA mutations, potentially revolutionizing treatment approaches.
A new drug called Olaparib has been approved for NHS use in treating breast and prostate cancer caused by inherited faulty BRCA-1 or BRCA-2 genes. The drug was previously available for women with advanced ovarian cancer. Sue Vincent, who joined a clinical trial for Olaparib after being told her ovarian cancer was inoperable, has been taking the drug since 2010 and her recent scans show no evidence of the disease. She credits the drug for giving her a quality of life she could only have dreamed about and is "delighted" it will be available for more patients.